Finally, we identified candidate drugs targeting the HDAC pathway as potentially useful strategies for promoting the infiltration of cytotoxic T cells into the microenvironment of high LS tumors, with the idea that this would enhance the efficacy of immunotherapies. Here, HDAC9 is linked to Leigh syndrome.